SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Growth in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 254,959 shares, a growth of 20.3% from the March 15th total of 211,974 shares. Based on an average daily volume of 96,355 shares, the short-interest ratio is currently 2.6 days. Currently, 0.4% of the shares of the company are short sold.

Analyst Ratings Changes

SOPH has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim raised their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, BTIG Research raised their price target on SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.50.

Insider Transactions at SOPHiA GENETICS

In related news, CEO Jurgi Camblong sold 17,473 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $5.00, for a total value of $87,365.00. Following the completion of the sale, the chief executive officer directly owned 3,646,967 shares in the company, valued at approximately $18,234,835. This trade represents a 0.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 181,300 shares of company stock valued at $880,323. Company insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently made changes to their positions in the company. Alta Wealth Advisors LLC bought a new stake in shares of SOPHiA GENETICS during the third quarter worth approximately $6,708,000. Susquehanna International Group LLP bought a new stake in shares of SOPHiA GENETICS during the third quarter worth approximately $88,000. XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $54,000. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the third quarter worth approximately $49,000. Institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at an NCI-designated center, a high-visibility customer that could drive recurring software usage and credibility in the U.S. market. Mount Sinai collaboration
• Positive Sentiment: Sector reinforcement — coverage of Mount Sinai using AI to speed genomic testing underscores demand for AI-driven genomics platforms, supporting the case for broader SOPHiA DDM adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst backing — recent analyst notes have raised price targets and issued buy ratings (e.g., BTIG, Guggenheim), giving investors a visible upside reference versus current levels and likely contributing to bullish sentiment.
• Neutral Sentiment: Insider selling disclosed — multiple insiders (CEO, President and others) sold tens of thousands of shares in mid‑April under pre‑arranged Rule 10b5‑1 plans, largely to cover tax withholding on vested awards. These are scheduled/tax-related sales (increasing float but not necessarily signaling negative inside-view). SEC Form 4 (example)
• Negative Sentiment: Profitability concerns persist — SOPH reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), negative margins and a large negative ROE; analysts still expect FY losses (~-0.96 EPS), which can cap valuation expansion despite commercial progress. Earnings & metrics

SOPHiA GENETICS Price Performance

Shares of SOPH opened at $5.28 on Friday. SOPHiA GENETICS has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The firm has a market capitalization of $361.63 million, a PE ratio of -10.35 and a beta of 1.04. The company’s 50-day moving average is $4.76 and its 200-day moving average is $4.73. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The firm had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. Equities analysts forecast that SOPHiA GENETICS will post -0.96 EPS for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.